Status:
RECRUITING
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
Lead Sponsor:
Centro di Riferimento Oncologico - Aviano
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which S...
Detailed Description
Colorectal cancer (CRC) is one of the most prevalent and deadly tumours in both men and women worldwide. An RNAi screening on 214 potential oncogenes described by the TCGA was performed and STARD3 was...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
- Age ≥18 years.
- Signed informed consent form.
- Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.
Exclusion
- Patients for which the tumour biobanking process could compromise the diagnostic assessments.
- Pregnancy or breast-feeding.
- History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Key Trial Info
Start Date :
May 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06136949
Start Date
May 22 2023
End Date
December 31 2032
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy, 33081